Cite
Bewersdorf JP, Zeidan AM. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?. Best Pract Res Clin Haematol. 2021;34(1):101245doi: 10.1016/j.beha.2021.101245.
Bewersdorf, J. P., & Zeidan, A. M. (2021). Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?. Best practice & research. Clinical haematology, 34(1), 101245. https://doi.org/10.1016/j.beha.2021.101245
Bewersdorf, Jan Philipp, and Zeidan, Amer M. "Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?." Best practice & research. Clinical haematology vol. 34,1 (2021): 101245. doi: https://doi.org/10.1016/j.beha.2021.101245
Bewersdorf JP, Zeidan AM. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?. Best Pract Res Clin Haematol. 2021 Mar;34(1):101245. doi: 10.1016/j.beha.2021.101245. Epub 2021 Jan 12. PMID: 33762100.
Copy
Download .nbib
